Aytu BioPharma Inc. (NASDAQ:AYTU) Given Consensus Rating of “Hold” by Brokerages

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been given a consensus rating of “Hold” by the five analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.3333.

Several equities analysts recently issued reports on the company. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th.

Aytu BioPharma Price Performance

NASDAQ AYTU opened at $2.61 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.16 and a quick ratio of 1.03. The stock’s fifty day moving average price is $2.57 and its 200 day moving average price is $2.44. Aytu BioPharma has a 1 year low of $1.20 and a 1 year high of $3.07. The company has a market cap of $28.01 million, a price-to-earnings ratio of -0.68 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The firm had revenue of $15.17 million during the quarter, compared to analyst estimates of $12.17 million. As a group, equities research analysts forecast that Aytu BioPharma will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Aytu BioPharma

Several hedge funds have recently made changes to their positions in AYTU. Persistent Asset Partners Ltd acquired a new position in shares of Aytu BioPharma in the 3rd quarter valued at $117,000. Dimensional Fund Advisors LP acquired a new stake in Aytu BioPharma during the 3rd quarter worth about $58,000. Two Sigma Investments LP grew its position in Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the period. FNY Investment Advisers LLC grew its position in Aytu BioPharma by 24,207.7% during the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after purchasing an additional 31,470 shares during the period. Finally, Daytona Street Capital LLC acquired a new stake in Aytu BioPharma during the 4th quarter worth about $26,000. 33.49% of the stock is owned by institutional investors and hedge funds.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.